Abstracts tagged "corticosteroids"

Abstract Number: 1007 • 2013 ACR/ARHP Annual Meeting
Dose Of Corticosteroid, Risk Of Adverse Events and Healthcare Resource Utilization In Systemic Lupus Erythematosus
Wei-Shi Yeh¹, Shih-Yin Chen², Kathleen McCarty³, Qian Li², Yuan-Chi Lee² and Nathalie Franchimont³, ¹Biogen Idec, Cambridge, MA, ²United BioSource Corporation, Lexington, MA, ³Biogen Idec Inc., Weston, MA
Background/Purpose: Gluco-corticosteroids (GCs) are frequently used to treat autoimmune disease and their chronic use has long been known to cause adverse events (AEs). The purpose…
Abstract Number: 2655 • 2012 ACR/ARHP Annual Meeting
Rapid and Effective Response to Immunosuppression in Treating Macrophage Activation Syndrome Associated with a Heterozygous Dominant Negative Mutation in RAB27a Leading to Decreased Cytolytic Activity
Randy Q. Cron¹, Mingce Zhang², Christina J. Bemrich-Stolz² and Timothy Beukelman¹, ¹Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Pediatrics, Univ of Alabama-Birmingham, Birmingham, AL
Background/Purpose: Hemophagocytic lymphohistiocytosis (HLH) is an often fatal disorder of infancy resulting from homozygous mutations in proteins involved in cytolysis (e.g. MUNC13-4, RAB27a, Perforin 1,…
Abstract Number: 2349 • 2012 ACR/ARHP Annual Meeting
Corticosterois Therapy Restaured Treg/Th17 Balance in Patients with Polimyalgia Rheumatica
Lorena Alvarez-Rodriguez¹, Marcos Lopez-Hoyos², Jaime Calvo-Alen³, Elena Aurrecoechea⁴, Teresa Ruiz Jimeno⁴, Ignacio Villa⁴, Carmen Gonzalez-Vela⁵ and Victor M. Martinez-Taboada¹, ¹Rheumatology, Hospital Universitario Marques de Valdecilla. IFIMAV, Santander, Spain, ²Immunology, Hospital Universitario Marques de Valdecilla. IFIMAV, Santander, Spain, ³Rheumatology, Hospital de Sierrallana. Torrelavega. Spain, Torrelavega, Spain, ⁴Rheumatology, Hospital de Sierrallana, Torrelavega, Spain, ⁵Pathology Anatomy, Hospital Universitario Marques de Valdecilla. IFIMAV, Santander, Spain
Background/Purpose: To characterize the levels of circulating T regulatory cells (Tregs) and Th17 cells in polymyalgia rheumatica (PMR). Methods: The study included 46 patients with…
Abstract Number: 2241 • 2012 ACR/ARHP Annual Meeting
Efficacy of Belimumab in Systemic Lupus Erythematosus Patients with High Baseline Disease Activity
Ann E. Clarke¹, Susan Manzi², Michelle Petri³, Richard Furie⁴, Ronald F. van Vollenhoven⁵, Simon Cooper⁶, Z. John Zhong⁶, William W. Freimuth⁶ and Arthur Weinstein⁷, ¹Division of Rheumatology, University of Calgary, Alberta, Calgary, AB, Canada, ²Division of Rheumatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴North Shore-LIJ Health System, Lake Success, NY, ⁵Karolinska University Hospital, Stockholm, Sweden, ⁶Human Genome Sciences, Inc., Rockville, MD, ⁷Washington Hospital Center, Washington, DC
Background/Purpose: To assess the efficacy of belimumab in patients with SLE who had high disease activity at baseline, as defined by SELENA-SLEDAI score ≥10. Methods: In…
Abstract Number: 1647 • 2012 ACR/ARHP Annual Meeting
Critical Management Decisions in Cardiac Neonatal Lupus: The Role of Fluorinated Steroids
Peter M. Izmirly¹, Sara Sahl¹, Amit Saxena², Nathalie Costedoat-Chalumeau³, Jean-Charles Piette⁴, Munther A. Khamashta⁵, Cecilia Pisoni⁶, Deborah Friedman⁷ and Jill P. Buyon¹, ¹Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ²Rheumatology, New York University School of Medicine, New York, NY, ³Internal Medicine, Assistance Publique-Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France, ⁴Department of Internal Medicine 1., CHU Pitié-Salpêtrière, Paris, France, ⁵Lupus Research Unit, The Rayne Institute, St Thomas Hospital, Kings College London School of Medicine, London, United Kingdom, ⁶Section of Rheumatology and Immunology, Centro de Educación, CEMIC, CABA, Argentina, ⁷Division of Pediatric Cardiology, New York Medical College, Valhalla, NY
Background/Purpose: Life-threatening cardiac manifestations of neonatal lupus (cardiac-NL) include complete block, endocardial fibroelastosis (EFE) and dilated cardiomyopathy (DCM), all supportive of intense fibrosis at the…
Abstract Number: 1651 • 2012 ACR/ARHP Annual Meeting
Higher Corticosteroid Doses Early in Disease Have A Long-Term Influence On Metabolic Syndrome in Systemic Lupus Erythematosus: Data from an International Inception Cohort
Ben Parker¹, Murray B. Urowitz², Dafna D. Gladman³, Mark Lunt⁴, Ian N. Bruce⁵ and Systemic Lupus International Collaborating Clinic (SLICC)⁶, ¹Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, ²Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, ⁵Manchester Academic Health Science Centre, Arthritis Research UK Epidemiology Unit and NIHR Manchester Musculoskeletal Biomedical Research Unit, The University of Manchester, Manchester, United Kingdom, ⁶Toronto
Background/Purpose: The Metabolic Syndrome (MetS) is a clustering of metabolic abnormalities associated with an increased risk of developing diabetes and atherosclerosis, and may add to…
Abstract Number: 1656 • 2012 ACR/ARHP Annual Meeting
Treatment of Systemic Necrotizing Vasculitides in Patients ≥65 Years Old: Results of the Multicenter Randomized Cortage Trial
Christian Pagnoux¹, Thomas Quemeneur², Jacques Ninet³, Elodie Perrodeau⁴, Elizabeth Diot⁵, Xavier Kyndt⁶, Benoit de Wazières⁷, jean-Luc Reny⁸, Xavier Puéchal⁹, Pierre-Yves Leberruyer¹⁰, Olivier Lidove¹¹, Philippe Vanhille¹², Pascal Godmer¹³, Aimé Albath-Sadiki¹⁴, Boris Bienvenu¹⁵, Pascal Cohen¹⁶, Luc Mouthon¹⁷, Philippe Ravaud⁴, Loic Guillevin¹⁸ and French Vasculitis Study Group (FVSG)¹⁹, ¹Internal Medicine, Department of Internal Medicine, National Referral Center for Necrotizing Vasculitides and Systemic Sclerosis, Hôpital Cochin, Assistance Publique – Hôpitaux de Paris, Université Paris – Descartes, Paris, France, Paris, France, ²Internal medicine, CHR de Valenciennes, Valenciennes, France, ³Department of Nephrology and Internal Medicine, Hôpital Edouard Herriot, Lyon, France, Lyon, France, ⁴Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, ⁵Department of Internal Medicine, Hôpital Bretonneau, Centre Hospitalier Régional Universitaire de Tours, Tours, France, Tours, France, ⁶Department of Nephrology and Internal Medicine, CH, Valenciennes, Valenciennes, France, ⁷Department of Internal Medicine and Gerontology, Hôpital Universitaire Carémeau, Nîmes, France, Nimes, France, ⁸Service de médecine interne générale Hôpitaux universitaires de Genève, Geneve, Switzerland, ⁹National Referral Center for Rare Systemic Auto-immune Diseases, Hôpital Cochin, AP-HP, Université Paris Descartes, Sorbonne Paris Cité, Paris, France, ¹⁰Hôpital Robert Debré, Centre Hospitalier Universitaire de Reims, Reims, France, Reims, France, ¹¹Médecine interne, Hôpital Croix-Saint-Simon, PARIS, France, ¹²Department of Nephrology and Internal Medicine, Hospital of Valenciennes, Valenciennes, France, Valenciennes, France, ¹³Department of Internal Medicine, Centre Hospitalier Bretagne Atlantique de Vannes, Vannes, France, ¹⁴Urc, Hôpital Cochin, AP-HP, Université Paris Descartes, Sorbonne Paris Cité, 27 rue du faubourg Saint Jacques, Paris, 75014, France, Paris, France, ¹⁵Médecine interne, CHU Côte de Nacre, CAEN, France, ¹⁶National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, ¹⁷Internal Medicine, Hopital Cochin, Paris, France, ¹⁸Internal Medicine, Cochin University Hospital, Paris, France, ¹⁹Department of Internal Medicine, National Referral Center for Necrotizing Vasculitides and Systemic Sclerosis, Hôpital Cochin, Assistance Publique – Hôpitaux de Paris, Université Paris – Descartes, Paris, France
Background/Purpose: To optimize the therapeutic strategy for the elderly with systemic necrotizing vasculitides (SNV; polyarteritis nodosa (PAN), granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) or…
Abstract Number: 1139 • 2012 ACR/ARHP Annual Meeting
Inhaled Nitrous Oxide Facilitates Access to Intra-Articular Corticosteroid Injections in Children with Juvenile Idiopathic Arthritis
Mercedes O. Chan¹, Ruth Wyllie² and H. E. Foster³, ¹Department of Pediatrics, Division of Pediatric Rheumatology, University of British Columbia and British Columbia's Children's Hospital, Vancouver, BC, Canada, ²Paediatric Rheumatology, Newcastle Hospitals, NHS Foundation Trust, Newcastle Upon Tyne, United Kingdom, ³Paediatric Rheumatology, Newcastle Hospitals NHS Foundation Trust, Great North Children's Hospital, Newcastle Upon Tyne, United Kingdom
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease of childhood affecting 1 in 1000 children. Medical management for arthritis often includes intra-articular…
Abstract Number: 184 • 2012 ACR/ARHP Annual Meeting
The Retrospective Review of 39 Intestinal Behcet’s Disease Focusing On the Requirement for the Immunosuppresive Drugs Other Than Corticosteroid
Yoshitaka Kimura¹, Kurumi Asako², Hirotoshi Kikuchi², Akiteru Takeuchi³ and Hajime Kono², ¹Department of Internal Medicine, Teikyo University school of medecine, Tokyo, Japan, ²Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan, ³6-7-8 Arakawa, Tokyo, Japan
Background/Purpose: To examine the demography, clinical characteristics, features of intestinal lesions, treatment, and prognosis in patients with the intestinal Behcet’s disease currently followed at a…
Abstract Number: 98 • 2012 ACR/ARHP Annual Meeting
How to Assess Risks for Pulmonary Infection in Patients Receiving Immunosuppressive Treatment for Rheumatic Diseases? A Report From a Large-Scale Prospective Cohort Study
Hayato Yamazaki¹, Ryoko Sakai¹, Ryuji Koike², Yasunari Miyazaki³, Michi Tanaka¹, Toshihiro Nanki¹, Kaori Watanabe¹, Shinsuke Yasuda⁴, Takashi Kurita⁵, Yuko Kaneko⁶, Yoshiya Tanaka⁷, Yasuhiko Nishioka⁸, Yoshinari Takasaki⁹, Kenji Nagasaka¹⁰, Koichi Amano¹¹, Shigeto Tohma¹², Makoto Dohi¹³, Takahiko Sugihara¹⁴, Haruhito Sugiyama¹⁵, Yasushi Kawaguchi¹⁶, Naohiko Inase¹⁷, Sae Ochi¹⁸, Hiroyuki Hagiyama¹⁹, Nobuyuki Miyasaka²⁰ and Masayoshi Harigai²¹, ¹Department of Pharmacovigilance, Tokyo Medical and Dental University, Tokyo, Japan, ²Clinical Research Center, Tokyo Medical and Dental University, Tokyo, Japan, ³Department of Integrated Pulmonology, Tokyo Medical and Dental University, Tokyo, Japan, ⁴Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ⁵Department of Medicine II, Hokkaido University, Sapporo, Japan, ⁶Dept of Internal Medicine, Keio Univ School of Medicine, Tokyo, Japan, ⁷The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ⁸Department of Respiratory Medicine & Rheumotology, The Univeristy of Tokushima Graduate School, Tokushima, Japan, ⁹Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ¹⁰Department of Rheumatology, Ome Municipal General Hospital, Ome, Japan, ¹¹Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan, ¹²Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, Sagamihara, Japan, ¹³Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ¹⁴Department of Medicine and Rheumatology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan, ¹⁵Division of Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan, ¹⁶Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ¹⁷Dept of Integrated Pulmonology, Tokyo Medical and Dental University, Tokyo, Japan, ¹⁸Department of Rheumatology, Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan, ¹⁹Department of Rheumatology, Yokohama-city Bay Red Cross Hospital, Yokohama, Japan, ²⁰Department of Medicine and Rheumatology and Global Center of Excellence Program, Tokyo Medical and Dental University, Tokyo, Japan, ²¹Dept of Pharmacovigilance, Tokyo Medical and Dental University, Tokyo, Japan
Background/Purpose: Patients with rheumatic diseases given immunosuppressive therapy are susceptible to various types of infections, especially pulmonary infections that affect their vital prognosis. The aim…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].